Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 800 results for "bristol myers squibb"

FDA letter calls for more data on Opdivo sBLA
Pharma Letter

Bristol-Myers Squibb to Present New Data across Multiple Blood...

Bristol-Myers Squibb to Present New Data Across Multiple Blood Cancers at the 57th Annual Meeting & Exposition of the American Society of Hematology Bristol-Myers Squibb Company ( NYSE:BMY ) today announced the presentation of clinical research ... Minyanville, 12 minutes ago
FDA letter calls for more data on Opdivo sBLA Pharma Letter, 1 hour ago

Bristol-Myers Looks Beyond Cancer To Build Portfolio

F or the past year, the talk concerning Bristol-Myers Squibb has focused on its cancer drugs. This is understandable, since Bristol-Myers ' (NYSE: BMY ) recently launched Opdivo is projected to take in nearly $9 billion a year by 2020, and looks ...
 Investor's Business Daily2 days ago

Bristol-Myers, U.N. strike generic hep C drug production pact for poor nations

Dive Brief: Daklinza (daclatasvir) will now be available as a generic drug in 112 low- and middle-income countries, based on an agreement between Bristol-Myers Squibb (BMS) and a UN-backed organization, the Medicines Patent Pool (MPP). Daklinza is ...
 BioPharma Dive5 days ago Bristol-Myers inks deal with UN-backed public health group for generic manufacture of daclatasvir  Seeking Alpha6 days ago Bristol-Myers signs deal with UN group for generic hep C drug  Reuters6 days ago Bristol-Myers Squibb signs licensing deal with UN-backed group for generic HCV drug Daklinza  FirstWord Pharma6 days ago

US FDA accepts Bristol-Myers Squibb's sBLA for Opdivo in patients with advanced RCC

Bristol-Myers Squibb Company announced that the US Food and Drug Administration (FDA) has accepted for filing and priority review a supplemental Biologics License Application (sBLA) for Opdivo for the treatment of patients with advanced renal cell ...
 PharmaBiz1 week ago FDA accepts for review Bristol-Myers' sBLA for Opdivo in advanced kidney cancer  Seeking Alpha1 week ago Bristol Myers Squibb : U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Advanced Renal Cell Carcinoma  4 Traders1 week ago FDA accepts to review Bristol-Myers Squibb's sBLA for Opdivo in advanced renal cell carcinoma  Pharmaceutical Business Review1 week ago

Investors Sell Shares of Bristol-Myers Squibb on Strength (BMY)

Investors sold shares of Bristol-Myers Squibb (NYSE:BMY) on strength during trading hours on Thursday, MarketBeat Ratings reports. $38.72 million flowed into the stock on the tick-up and $57.65 million flowed out of the stock on the tick-down, for a ...
 MyInforms3 days ago Traders Sell Shares of Bristol-Myers Squibb on Strength on Insider Selling (BMY)  WKRB News4 days ago Shareholders of Bristol-Myers Squibb Applaud Decision to Share License for Hepatitis C Drug  Interfaith Center on Corporate Responsibility5 days ago January 2018 Options Now Available For Bristol-Myers Squibb (BMY)  Forbes.com1 week ago

Global Orphan Drugs Market To Witness Exponential Growth - Bristol-Myers Squibb, Novartis, Roche, GlaxoSmithKline, and Merck Among Other Major Market Players

By PR Newswire Article Rating: November 20, 2015 06:00 AM EST BANGALORE , November 20, 2015 /PRNewswire/ -- Mordor Intelligence is pleased to announce the publication of the report on Global Orphan Drugs Market on November 20, 2015 ...
 Ulitzer1 week ago Global Biological Drugs Market - Industry Analysis,Trends and Forecast to 2020  Digital Journal4 days ago

Health Signing of a license by the Medicines Patent Pool for a hepatitis C medication (11.23.15)

We applaud the royalty-free license just signed by the pharmaceutical company Bristol-Myers-Squibb and the Medicines Patent Pool established
 France Diplomatie5 days ago In Deal With Medicines Patent Pool, Bristol-Myers Squibb Agrees To Allow Generic Versions Of HCV Treatment To Be Sold In LMICs  Kaiser Network.org5 days ago BMS and Medicines Patent Pool collaborate to increase Hep C medicine access  Pharmafile5 days ago The Medicines Patent Pool Signs Licence with Bristol-Myers Squibb to Increase Access to Hepatitis C Medicine daclatasvir  Wall Street Business Network6 days ago

Bristol-Myers Squibb Has No Cure For Your Portfolio

Bristol-Myers Squibb (NYSE:BMY) has a long and proud history of value creation for its shareholders. Jeremy Siegel went through the original S&P 500 companies in his book, "The Future For Investors", and found out that Bristol-Myers Squibb was ...
 TeleTrader.com1 week ago

Analysts Set Bristol-Myers Squibb PT at $70.38 (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) has been given an average recommendation of Buy by the eighteen brokerages that are covering the stock, MarketBeat.Com reports. Six analysts have rated the stock with a hold rating and ten have given a buy rating to ...
 SleekMoney3 hours ago

Bristol-Myers Squibb Expected to Announce Earnings of $0.26 Per Share (NYSE:BMY)

Equities analysts expect Bristol-Myers Squibb (NYSE:BMY) to post $0.26 earnings per share for the current quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Bristol-Myers Squibb's earnings. The highest EPS estimate ...
 SleekMoney6 hours ago Zacks: Brokerages Anticipate Bristol-Myers Squibb to Post $0.26 Earnings Per Share (NYSE:BMY)  Ticker Report2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - bristol myers squibb
Get updated on latest news & your favorite topics right in your inbox!
More     Less